Výsledky vyhledávání - "Long Xuan Trinh"

Tyrosine Kinase Inhibitors as Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase

Autor: Hagop M. Kantarjian, Farhad Ravandi, Jorge E. Cortes, Guillermo Garcia-Manero, Richard E. Champlin, Long Xuan Trinh, Lynne V. Abruzzo, Tapan M. Kadia, Sherry Pierce, Srdan Verstovsek, Maro Ohanian, Elias Jabbour, Susan O'Brien, Alessandra Ferrajoli, Alfonso Quintás-Cardama, Gautam Borthakur, Raja Luthra, Mona Lisa Alattar

Publikováno v: Clinical lymphoma, myeloma & leukemia, vol 14, iss 2

Background Accelerated phase CML most frequently represents a progression state in CML. However, some patients present with AP features at the time of diagnosis. There is limited information on the outcome of these patients who received TKIs as initi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::228af92cacc419ea1f0d7203dc730208
https://europepmc.org/articles/PMC3959284/

Zobrazit plný text záznamu

Hyponatraemia, rhabdomyolysis, alterations in blood pressure and persistent mydriasis in patients envenomed by Malayan kraits (Bungarus candidus) in southern Viet Nam

Autor: Quyen Le Khac, Long Xuan Trinh, Kiem Xuan Trinh, David A. Warrell

Publikováno v: Toxicon : official journal of the International Society on Toxinology. 56(6)

Between 1998 and 2007, 42 patients admitted to Choray hospital, Ho Chi Minh City, and to two hospitals in adjacent regions in southern Viet Nam brought the Malayan kraits (Bungarus candidus) that had been responsible for biting them. Half of the pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c6c5981c9527411382f66b4dc39072
https://pubmed.ncbi.nlm.nih.gov/20637219

Zobrazit plný text záznamu

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy

Autor: Long Xuan Trinh, Young Kwang Chae, Preetesh Jain, Susan Lerner, Ohad Benjamini, Xuemei Wang, Michael J. Keating

Publikováno v: Blood. 120:2900-2900

Abstract 2900 Increasing use of chemo-immunotherapy in CLL has raised concerns over the carcinogenic effect of FCR regimen. Fludarabine based regimen in relapsed CLL has been reported to be predisposed to a higher risk of other cancers as compared to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f6899e88f89b0d1bed055fbeb0eee4a
https://doi.org/10.1182/blood.v120.21.2900.2900

Zobrazit plný text záznamu

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Autor: Ohad Benjamini, Michael J. Keating, Young Kwang Chae, Preetesh Jain, William G. Wierda, Long Xuan Trinh, Susan Lerner, Zeev Estrov, Xuemei Wang

Publikováno v: Blood. 120:3931-3931

Abstract 3931 Introduction - Statins are a class of drugs used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase. In addition, statins possess anti-inflammatory, immunomodulatory, antioxidant, and cell growth inhibitory propertie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e642dbadff3fc7d867cbe0587263092b
https://doi.org/10.1182/blood.v120.21.3931.3931

Zobrazit plný text záznamu

Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL

Autor: Long Xuan Trinh, Zeev Estrov, Michael J. Keating, Young Kwang Chae

Publikováno v: Blood. 120:2904-2904

Abstract 2904 Background: Aspirin is known to induce apoptosis in B-chronic lymphocytic leukemia (B-CLL) cells in a dose and time dependent manner (Gil et al. Blood 1998). Aspirin generates DNA fragmentation, caspase activation, and proteolytic cleav

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e849b1f89125017780dd87aaef169c1d
https://doi.org/10.1182/blood.v120.21.2904.2904

Zobrazit plný text záznamu

Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes

Autor: Mylene T. Truong, Susan C. Smith, Xuemei Wang, Long Xuan Trinh, Michael J. Keating, Edith M. Marom, Susan Lerner, Rachel L. Sargent, Ellen J. Schlette, Lorenzo Falchi, Alessandra Ferrajoli

Publikováno v: Blood. 120:927-927

Abstract 927 Introduction. Richter's transformation (RT) occurs in 2–8% of pts with chronic lymphocytic leukemia (CLL) and is associated with poor prognosis. Moreover, pts with CLL often show clinical and/or histologic features of aggressive diseas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8d8eb982260e6f146939136503ff7c4a
https://doi.org/10.1182/blood.v120.21.927.927

Zobrazit plný text záznamu

Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP)

Autor: Tapan M. Kadia, Guillermo Garcia-Manero, Elizabeth M. Burton, Long Xuan Trinh, Elias Jabbour, Hagop M. Kantarjian, Jorge E. Cortes, Alessandra Ferrajoli, Maro Ohanian, Farhad Ravandi, Susan O'Brien, Srdan Verstovsek, Alfonso Quintás-Cardama, Gautam Borthakur

Publikováno v: Blood. 118:3779-3779

Abstract 3779 Background: Some patients (pts) with chronic myeloid leukemia (CML) present with features of accelerated phase (AP) at the time of diagnosis. Imatinib, dasatinib, and nilotinib are standard initial tyrosine kinase inhibitor (TKI) therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::553bf9db447e8e94645280d1678a2ba6
https://doi.org/10.1182/blood.v118.21.3779.3779

Zobrazit plný text záznamu

Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC)

Autor: Guillermo Garcia-Manero, Alessandra Ferrajoli, Stefan Faderl, Francesco Paolo Tambaro, Long Xuan Trinh, Susan Lerner, Hagop M. Kantarjian, Michael J. Keating, Susan O'Brien, William G. Wierda, Jan A. Burger

Publikováno v: Blood. 118:981-981

Abstract 981 Acute leukemia (AL) and myelodysplastic syndrome (MDS) are uncommon in patients (pts) with CLL and have mainly been attributed with exposure to chemotherapy and radiotherapy. In contrast, CLL is frequently associated with second solid ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ac1ae30c5c1666ecbbb20cb7d473006
https://doi.org/10.1182/blood.v118.21.981.981

Zobrazit plný text záznamu

Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML)

Autor: Alfonso Quintás-Cardama, Hagop M. Kantarjian, Jan A. Burger, Susan O'Brien, Jorge E. Cortes, Elizabeth M. Burton, Long Xuan Trinh, Elias Jabbour, Theresa Liu-Dumlao, Farhad Ravandi, Yesid Alvarado, Alessandra Ferrajoli

Publikováno v: Blood. 118:2761-2761

Abstract 2761 Background: Frontline treatment with tyrosine kinase inhibitors (TKIs) has improved prognosis for patients with chronic myelogenous leukemia (CML). Myelosuppression is the most common adverse event (AE) seen during therapy with frontlin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::faacaa88715a2c85fd38d62b7a4657ca
https://doi.org/10.1182/blood.v118.21.2761.2761

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání